| 2012 | 2013 | 2014 | 2015 | 2018 (projected) | Innoviva Current Assets | 261,133,000 | 483,198,000 | 252,182,000 | 214,325,000 | 192,892,500 | Innoviva Total Assets | 368,582,000 | 681,255,000 | 521,654,000 | 408,932,000 | 368,038,800 |
Still ambivalent about Innoviva?
 | By Rifka Kats | Macroaxis Story |
Today post will go over Innoviva. I will look into why albeit cyclical Innoviva disturbance, the long term basic indicators of the company are still strong. This firm Piotroski F Score is 7 - Strong. Given the investment horizon of 30 days, Innoviva is expected to under-perform the market. In addition to that, the company is 3.35 times more volatile than its market benchmark. It trades about -0.18 of its total potential returns per unit of risk. The market is currently generating roughly 0.21 per unit of volatility. We found thirty-seven available reported financial drivers for Innoviva which can be compared to its competitors. To make sure the equity is not overpriced, please check out all Innoviva fundamentals including its Price to Earning, Cash per Share, Price to Earnings To Growth, as well as the relationship between Gross Profit and Book Value Per Share . Given that Innoviva has Price to Earning of 3.98X, we strongly advise you confirm Innoviva regular market performance to make sure the company can sustain itself down the road. Use Innoviva to protect your portfolios against small markets fluctuations. The stock experiences somewhat bearish sentiment, but market may correct it shortly. Check odds of Innoviva to be traded at $13.39 in 30 days.
Macroaxis uses a strict editorial review process to publish stories and blog posts. Our publishers support our company and may receive a small commission when the partner links or references are utilized. Commissions do not affect the opinions or evaluations of our editorial team. The information our editors and media partners deliver is confidential and licensed for your sole use as a Macroaxis user. We reserve all rights to the content of this article, and therefore copying or distributing this story in whole or in part is strictly prohibited.
Reviewed by Raphi Shpitalnik
INOVA TECHNOLOGY currently holds roughly 114.91M in cash with 223.53M of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.14. Innoviva dividends can provide a clue to current valuation of the stock. The firm is not expected to issue dividends this year as it trying to preserve or re-invest any of the funds available for distribution to stakeholders. About 34.0% of the company shares are held by company insiders. The company has Price/Earnings To Growth (PEG) ratio of 0.39. Innoviva last dividend was issued on 2015-09-08. The entity had 1:100 split on 2014-06-03.
Please note, it is not enough to conduct a financial or market analysis of a single entity such as Innoviva. Your research has to be compared to or analyzed against Innoviva's peers to derive any actionable benefits. When done correctly, Innoviva's competitive analysis will give you plenty of quantitative and qualitative data to validate your investment decisions or develop an entirely new strategy toward taking a position in Innoviva.
Investing in Innoviva, just like investing in any other equity instrument, is characterized by a strong risk-return correlation. High risks mean high returns and low risk means lower expected returns. Risk management is the act of identifying and assessing the potential risk and developing strategies to minimize these risks and earn maximum possible profits while holding Innoviva along with other instruments in the same portfolio. Using conventional technical analysis and fundamental analysis to select individual securities into a portfolio complements risk management and adds value to overall investors' investing strategies.
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Innoviva's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
How important is Innoviva's Liquidity
Innoviva financial leverage refers to using borrowed capital as a funding source to finance Innoviva ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. Innoviva financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Financial leverage can amplify the potential profits to Innoviva's owners, but it also increases the potential losses and risk of financial distress, including bankruptcy, if the firm cannot cover its debt costs. The degree of Innoviva's financial leverage can be measured in several ways, including by ratios such as the debt-to-equity ratio (total debt / total equity), equity multiplier (total assets / total equity), or the debt ratio (total debt / total assets). Please check the breakdown between Innoviva's total debt and its cash.
Innoviva Gross Profit
Innoviva Gross Profit growth is one of the most critical measures in evaluating the company. The Gross Profit growth rate is calculated simply by comparing Innoviva previous period's values with its current period's values. Each time period you're measuring should be of equal lengths the increase or decrease, in a company's Gross Profit between two periods. Here we show Innoviva Gross Profit growth over the last 10 years. Please check Innoviva's gross profit and other fundamental indicators for more details.
Innoviva Correlation with Peers
Investors in Innoviva can reduce exposure to individual asset risk by holding a diversified portfolio of assets in addition to a long position in Innoviva. Diversification will allow for the same portfolio return with reduced risk. The correlation table of Innoviva and its peers is a two-dimensional matrix that shows the correlation coefficient between pairs of securities Innoviva is related in some way. The cells in the table are color-coded to highlight significantly positive and negative relationships. Each cell shows the correlation between one pair of equities and can be used to run pair trading strategies or create efficient portfolios with your current brokerage. Please check volatility of Innoviva for more details
Another angle On Innoviva
The recent decline in stock price may raise some interest from investors. The Stock closed today at a share price of 13.78 on 197906 in trading volume. The company directors and management have failed to build on market volatilities in March. However, diversifying your overall positions with Innoviva may protect your principal portfolio during upcoming market swings. The stock standard deviation of daily returns for 30 days (very short) investing horizon is currently 2.1529. The current volatility is consistent with the ongoing market swings in March 2019 as well as with Innoviva unsystematic, company specific events. Innoviva is trading at 13.80 which is 1.5 percent decrease. Today lowest is 13.78. Innoviva Gross Profit is increasing over the last 5 years. Innoviva Trade and Non Trade Payables is somewhat stable at the moment. Furthermore, Innoviva Invested Capital Average is somewhat stable at the moment.
To conclude, we see that Innoviva Moves slightly opposite to market. The company is overvalued with high odds of financial distress within the next 24 months. Our overall buy vs. sell advice on the company is Strong Sell.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectEditorial Staff
This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Rifka Kats do not own shares of Innoviva. Please refer to our Terms of Use for any information regarding our disclosure principles.